NCT00900042|Completed
SWOG-9023, DNA Analysis of Tumor Tissue From Patients With Metastatic Kidney Cancer
Cytogenetic and Flow Cytometric Analysis of : Renal Cell Carcinoma: A Companion Protocol to SWOG-8949
Loading search results
Cytogenetic and Flow Cytometric Analysis of : Renal Cell Carcinoma: A Companion Protocol to SWOG-8949
Sponsor study identifier
Secondary identifiers
OTHER · SWOG
NIH
observational
34
0 countries
N/A
Study Start
July 1993
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
December 2002
Actual (reported)Study Completion
January 2003
Actual (reported)RATIONALE: DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment. PURPOSE: This laboratory study is analyzing the DNA in tumor tissue from patients with metastatic kidney cancer.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2003
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 1993
Date type not reportedThis date has not been verified as actual or estimated.
December 2002
Actual (reported)January 2003
Actual (reported)May 9, 2009
Actual (reported)May 12, 2009
Actual (reported)Number of successes per number of evaluable samples
Success is defined as obtaining at least 10 analyzable metaphases.
up to 4 years after registration
Number of abnormalities per number of successes
Abnormality is defined as at lease one clonal chromosomal abnormality.
up to 4 years after registration
Correlation of tumor response to treatment with the type and number of abnormalities
Abnormality is defined as at lease one clonal chromosomal abnormality.
up to 4 years after registration
Correlation of time from diagnosis to development of metastatic disease with the type and number of abnormalities
Abnormality is defined as at lease one clonal chromosomal abnormality.
up to 4 years after registration
Correlation of time from first diagnosis of metastatic disease until death with the type and number of abnormalities
Abnormality is defined as at lease one clonal chromosomal abnormality.
up to 4 years after registration
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Tumor diagnostic tissue
Robert P. Whitehead, MD
University of Texas
34 participants (actual enrollment reported by the registry).
First Submitted
May 9, 2009
First Posted
May 12, 2009
Study Start
July 1993
Date type not reportedThis date has not been verified as actual or estimated.
S0312, Gemcitabine and Capecitabine in Treating Patients With Advanced Renal Cell (Kidney) Cancer
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Primary Completion
December 2002
Actual (reported)Study Completion
January 2003
Actual (reported)Last Updated
February 25, 2014
Record last verified: 2014-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: